Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1F | O60840 | 1/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.74 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.74 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | GSK3B | P49841 | 16/20 | 0.57 |
| ▸ | TOP2A | P11388 | 2/20 | 0.55 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8201556 | 0.89 | CACNA1F (0.78) | CACNA1FPOLBMAPK1CACNA1DKCNH2 | |
| SCHEMBL10123852 | 0.86 | CACNA1F (0.74) | CACNA1FPOLBMAPK1CACNA1DKCNH2 | |
| SCHEMBL12665464 | 0.86 | KCNH2 (0.74) | CACNA1FPOLBMAPK1CACNA1DKCNH2 | |
| SCHEMBL9147650 | 0.86 | CACNA1F (0.79) | CACNA1FPOLBMAPK1CACNA1DKCNH2 | |
| SCHEMBL2739184 | 0.86 | CACNA1F (0.73) | CACNA1FPOLBMAPK1CACNA1DKCNH2 | |
| Sparfloxacin SCHEMBL41311 | 0.85 | KCNH2 (1.00) | CACNA1FPOLBMAPK1CACNA1DKCNH2 | |
| Sparfloxacin SCHEMBL1387460 | 0.85 | KCNH2 (1.00) | CACNA1FPOLBMAPK1CACNA1DKCNH2 | |
| Sparfloxacin SCHEMBL2637186 | 0.85 | KCNH2 (1.00) | CACNA1FPOLBMAPK1CACNA1DKCNH2 | |
| Sparfloxacin SCHEMBL29365159 | 0.85 | KCNH2 (1.00) | CACNA1FPOLBMAPK1CACNA1DKCNH2 | |
| SCHEMBL10679561 | 0.85 | CACNA1F (0.78) | CACNA1FPOLBMAPK1CACNA1DKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261950-A1 | Compounds that inhibit cholinesterase | ACHE, BCHE, CHAT | CACNA1F 1591/4885POLB 2231/4885MAPK1 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.